MedPage Today (8/4, George) reports, “Blood biomarkers may change how Alzheimer’s disease is diagnosed but aren’t ready for widespread use in primary care yet,” investigators concluded while presenting “the Alzheimer’s Association’s appropriate use recommendations for blood biomarkers at the 2022 Alzheimer’s Association International Conference.” For that reason, “the Alzheimer’s Association working group of clinicians and researchers did not recommend blood-based biomarkers for population risk screening or as direct-to-consumer tests at this time.” A review article published online in the journal Alzheimer’s & Dementia discusses blood-based biomarkers. (SOURCE: APA Headlines)